Artikel ; Online: Dapagliflozin in patients with critical illness: rationale and design of the DEFENDER study.
Critical care science
2023 Band 35, Heft 3, Seite(n) 256–265
Abstract: Background: Critical illness is a major ongoing health care burden worldwide and is associated with high mortality rates. Sodium-glucose cotransporter-2 inhibitors have consistently shown benefits in cardiovascular and renal outcomes. The effects of ... ...
| Abstract | Background: Critical illness is a major ongoing health care burden worldwide and is associated with high mortality rates. Sodium-glucose cotransporter-2 inhibitors have consistently shown benefits in cardiovascular and renal outcomes. The effects of sodium-glucose cotransporter-2 inhibitors in acute illness have not been properly investigated. Methods: DEFENDER is an investigator-initiated, multicenter, randomized, open-label trial designed to evaluate the efficacy and safety of dapagliflozin in 500 adult participants with acute organ dysfunction who are hospitalized in the intensive care unit. Eligible participants will be randomized 1:1 to receive dapagliflozin 10mg plus standard of care for up to 14 days or standard of care alone. The primary outcome is a hierarchical composite of hospital mortality, initiation of kidney replacement therapy, and intensive care unit length of stay, up to 28 days. Safety will be strictly monitored throughout the study. Conclusion: DEFENDER is the first study designed to investigate the use of a sodium-glucose cotransporter-2 inhibitor in general intensive care unit patients with acute organ dysfunction. It will provide relevant information on the use of drugs of this promising class in critically ill patients. Clinicaltrials.gov registry: NCT05558098. |
|---|---|
| Mesh-Begriff(e) | Adult ; Humans ; Critical Illness/therapy ; Multiple Organ Failure/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Multicenter Studies as Topic |
| Chemische Substanzen | dapagliflozin (1ULL0QJ8UC) ; Sodium-Glucose Transporter 2 Inhibitors |
| Sprache | Portugiesisch |
| Erscheinungsdatum | 2023-12-22 |
| Erscheinungsland | Brazil |
| Dokumenttyp | Clinical Trial Protocol ; Journal Article |
| ISSN | 2965-2774 |
| ISSN (online) | 2965-2774 |
| DOI | 10.5935/2965-2774.20230129-en |
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.
Fernleihe an ZB MED
Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.